• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fractyl Health Inc.

    2/16/24 9:43:25 PM ET
    $GUTS
    Get the next $GUTS alert in real time by email
    SC 13G 1 d775588dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO

    FILED PURSUANT TO § 240.13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Fractyl Health, Inc.

    (Name of Issuer)

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

    35168W103

    (CUSIP Number)

    Christopher McCain

    General Catalyst Partners

    20 University Road, 4th Floor, Cambridge, MA 02138

    (617) 234-7000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 35168W103    13G   

     

     1.   

     Names of Reporting Persons

     

     General Catalyst GP V, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     4,884,186

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     4,884,186

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,884,186

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     10.02%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 35168W103    13G   

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Partners V, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     4,884,186

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     4,884,186

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,884,186

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     10.02%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 35168W103    13G   

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Group V, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     4,884,186

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     4,884,186

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,884,186

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     10.02%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 35168W103    13G   

     

     1.   

     Names of Reporting Persons

     

     GC Entrepreneurs Fund V, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     4,884,186

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     4,884,186

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,884,186

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     10.02%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 35168W103    13G   

     

    Item 1.

    (a) Name of Issuer: Fractyl Health, Inc.

    (b) Address of Issuer’s Principal Executive Offices:

    17 Hartwell Avenue, Lexington, Massachusetts 02421

     

    Item 2.

    (a) Name of Person Filing:

    This joint statement on Schedule 13G is being filed by General Catalyst GP V, LLC, a Delaware limited liability company (“GCGPV”), General Catalyst Partners V, L.P., a Delaware limited partnership (“GCGV GPLP”), General Catalyst Group V, L.P., a Delaware limited partnership (“GCGV”) and GC Entrepreneurs Fund V, L.P., a Delaware limited partnership (“GCEV”) (together, the “Reporting Persons”).

    GCGPV is the general partner of GCGV GPLP, which is the general partner of GCGV and GCEV. GCGPV is controlled by a group of three or more individuals, or the Managing Directors, having shared voting and dispositive control over the shares held by GCGV and GCEV. Each of the Managing Directors disclaims beneficial ownership of the securities held by GCGV and GCEV except to the extent of his or her pecuniary interest therein, if any.

    The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.

    (b) Address of Principal Business Office or, if none, Residence:

    20 University Road, 4th Floor, Cambridge, MA 02138

    (c) Citizenship:

    Each of GCGV GPLP, GCGV, and GCEV is a limited partnership organized under the laws of the State of Delaware. GCGPV is a limited liability company organized under the laws of the State of Delaware. Each of the Managing Directors is a U.S. citizen.

    (d) Title of Class of Securities:

    Common Stock, par value $0.0001 per share.

    (e) CUSIP Number: 35168W103

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


    CUSIP No. 35168W103    13G   

     

    (a) Amount beneficially owned:

    GCGV is the record owner of 4,784,323 shares and GCEV is the record owner of 99,863 shares (collectively, the “Record Shares”).

    General Catalyst Group Management Holdings GP, LLC, a Delaware limited liability company (“GCGMH LLC”), is the general partner of General Catalyst Group Management Holdings, L.P., a Delaware limited partnership (“GCGMH”), which is the manager of General Catalyst Group Management, LLC, a Delaware limited liability company (“GCGM”), which is the manager of GCGPV. GCGV GPLP is the sole general partner of GCGV and GCEV. GCGPV is the sole general partner of GCGV GPLP.

    As the general partner of GCGMH, GCGMH LLC may be deemed to beneficially own the Record Shares. As the sole general partner of GC V and GCEV, GCGV GPLP may be deemed to beneficially own the Record Shares. As the sole general partner of GCGV GPLP, GCGPV may be deemed to beneficially own the Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each Reporting Person may be deemed to share the power and direct the disposition and vote of the Record Shares. Both GCGMH LLC and GCGPV are controlled by a group of three or more individuals, or the Managing Directors, having shared voting and dispositive control over the shares held by GC V and GCEV. Under the so-called “rule of three,” because voting and dispositive decisions are made by a majority of both GCGMH LLC and GCGPV Managing Directors, no one of the Managing Directors is deemed to be a beneficial owner of the Issuer’s securities held by GCGV and GCEV.

    (b) Percent of class:

    See Line 11 of cover sheets. The percentages set forth on the cover sheets for each Reporting Person are calculated based on This percentage is calculated based upon 48,707,200 shares of common stock, par value $0.00001 per share, outstanding of Fractyl Health, Inc. (the “Issuer”) following the closing of the Issuer’s initial public offering, as set forth in the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on February 2, 2024, after giving effect to an additional 1,099,999 shares that may be issued and sold by the Issuer to the underwriters pursuant to the underwriters’ option.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Line 5 of cover sheets.

    (ii) Shared power to vote or to direct the vote

    See Line 6 of cover sheets.

    (iii) Sole power to dispose or to direct the disposition of

    See Line 7 of cover sheets.

    (iv) Shared power to dispose or to direct the disposition of

    See Line 8 of cover sheets.

    Each of the Reporting Persons disclaims beneficial ownership of the Record Shares except to the extent of its or pecuniary interest therein, if any.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.


    CUSIP No. 35168W103    13G   

     

    Item 8.

    Identification and Classification of Members of the Group

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

    Material to be Filed as Exhibits.

     

    Exhibit 1 –   Agreement regarding joint filing of Schedule 13G.


    CUSIP No. 35168W103    13G   

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2024

     

    GENERAL CATALYST GP V, LLC
          By:  

    /s/ Christopher McCain

          Christopher McCain
          Chief Legal Officer
    GENERAL CATALYST GROUP V, L.P.
    By:   GENERAL CATALYST PARTNERS V, L.P.
      its General Partner
      By:     GENERAL CATALYST GP V, LLC
            its General Partner
            By:  

    /s/ Christopher McCain

              Christopher McCain
              Chief Legal Officer
    GENERAL CATALYST PARTNERS V, L.P.
    By:   GENERAL CATALYST GP V, LLC
      its General Partner
            By:  

    /s/ Christopher McCain

             

    Christopher McCain

    Chief Legal Officer

    GC ENTREPRENEURS FUND V, L.P.
      By:   GENERAL CATALYST PARTNERS V, L.P.
            its General Partner
      By:   GENERAL CATALYST GP V, LLC
            its General Partner
            By:  

    /s/ Christopher McCain

              Christopher McCain Chief
              Legal Officer
    Get the next $GUTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

      First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in 2026, pending CTA authorization BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D), today announced that it has submitted the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, the Company's gene therapy candidate from its Rejuva platform. RJVA-001 is de

      5/19/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Conaway Samuel

      4/A - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 8:18:31 PM ET
      $GUTS
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS
    • Director Schulman Amy W bought $9,964 worth of shares (8,550 units at $1.17) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/17/25 5:09:08 PM ET
      $GUTS

    $GUTS
    Financials

    Live finance-specific insights

    See more
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025 Company plans to submit first Clinical Trial Application (CTA) module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 D

      3/3/25 4:05:00 PM ET
      $GUTS

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Fractyl Health

      Evercore ISI initiated coverage of Fractyl Health with a rating of Outperform

      2/28/24 8:22:09 AM ET
      $GUTS
    • Morgan Stanley initiated coverage on Fractyl Health with a new price target

      Morgan Stanley initiated coverage of Fractyl Health with a rating of Overweight and set a new price target of $18.00

      2/27/24 6:55:29 AM ET
      $GUTS
    • BofA Securities initiated coverage on Fractyl Health with a new price target

      BofA Securities initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $26.00

      2/27/24 6:55:03 AM ET
      $GUTS

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/14/24 4:30:50 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/13/24 5:17:27 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

      2/16/24 9:43:25 PM ET
      $GUTS

    $GUTS
    SEC Filings

    See more
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 9:27:21 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 7:00:08 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/13/25 4:05:11 PM ET
      $GUTS

    $GUTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

      BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

      4/2/24 8:00:00 AM ET
      $GUTS
    • Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

      LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

      2/20/24 8:38:00 AM ET
      $GUTS